Molecular abnormalities in lung cancer

Journal of Clinical Oncology

Volumn 16, Issue 3, 1998, Pages 1207-1217

  Salgia, Ravi ^a   Skarin, Arthur T ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; ONCOPROTEIN; PROTEIN BCL 2; PROTEIN P16; PROTEIN P53; RAS PROTEIN; RETINOBLASTOMA PROTEIN;

APOPTOSIS; CHROMOSOME ABERRATION; CLINICAL TRIAL; GENE EXPRESSION; GENE MUTATION; GENE THERAPY; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; ONCOGENE; ONCOGENE C ERB; ONCOGENE K RAS; ONCOGENE MYC; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REVIEW; TUMOR SUPPRESSOR GENE;

EID: 0031934761     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.3.1207     Document Type: Review

References (148)

1. Parker S, Tong T, Bolden S, et al: Cancer statistics, 1997. CA Cancer J Clin 47:5-27, 1997
2. Ginsberg R, Kris M, Armstrong J: Cancer of the lung, in De Vita V, Hellman S, Rosenberg SA (eds): Principles and Practice of Oncology (ed 4). Philadelphia, PA, Lippincott-Raven, 1993, pp 673-758
3. Skarin A: Respiratory tract and head and neck cancer, in Rubenstein E, Federman D (eds): Scientific American Medicine. New York, Scientific American, 1994, pp 1-35
4. Skarin A: Analysis of long term survivors with small-cell lung cancer. Chest 103:440S-444S, 1993
5. Rowinsky E, Ettinger D: Drug development and new drugs for lung cancer, in Pass HI, Mittchell JB, Johnson DH, Turrisi A (eds): Lung Cancer: Principles and Practice. Philadelphia, PA, Lippincott-Raven, 1996, pp 793-810
6. Testa J: Chromosome alterations in human lung cancer, in Mitchell J, Johnson D, Turrisi A (eds): Lung Cancer: Principles and Practice. Philadelphia, PA, Lippincott-Raven, 1996, pp 55-71
7. Hibi K, Takahashi T, Yamakawa K, et al: Three distinct regions involved in 3p deletion in human lung cancer. Oncogene 7:445-449, 1992
8. Otterson G, Lin A, Kaye F: Genetic etiology of lung cancer. Oncology 6:97-112, 1992
9. Graziano S, Pfeifer A, Testa J, et al: Involvement of the RAF1 locus, at band 3p25, in the 3p deletion of small-cell lung cancer. Genes Chromosomes Cancer 3:283-293, 1991
10. Croce C: Genetic approaches to the study of the molecular basis of human cancer. Cancer Res 51:5015S-5018S, 1991 (suppl)
11. LaForgia S, Morse B, Levy J, et al: Receptor protein-tyrosine phosphatase gamma is a candidate tumor suppressor gene at human chromosome region 3p21. Proc Natl Acad Sci USA 86:5036-5040, 1991
12. Latif F, Tory K, Gnarra J, et al: Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 260:1317-1320, 1993
13. Sozzi G, Veronese M, Negrini M, et al: The FHIT gene at 3p14.2 is abnormal in lung cancer. Cell 85:17-26, 1996
14. Huebner K, Hadaczek P, Siprashvili Z, et al: The FHIT gene, a multiple tumor suppressor gene encompassing the carcinogen sensitive chromosome fragile sige, FRA3B. Biochem Biophys Acta Rev Ca 1332:65-70, 1997
15. Ohata H, Emi M, Fujiwara Y, et al: Deletion mapping of the short arm of chromosome 8 in non-small cell lung carcinoma. Genes Chromosomes Cancer 7:85-88, 1993
16. Merlo A, Gabrielson E, Askin F, et al: Frequent loss of chromosome 9 in human primary non-small cell lung cancer. Cancer Res 54:640-642, 1994
17. Shapiro G, Rollins B: p16INK4A as a human tumor suppressor. Biochim Biophys Acta Rev Cancer 1242:165-169, 1996
18. Wiest J, Franklin W, Otstot J, et al: Identification of a novel region of homozygous deletion on chromosome 9p in squamous cell carcinoma of the lung: The location of a putative tumor suppressor gene. Cancer Res 57:1-6, 1997
19. Fong F, Zimmerman P, Smith P: Lung pathology: The molecular genetics of non-small cell lung cancer. Pathology 27:295-301, 1995
20. Devereux TR, Taylor JA, Barrett JC: Molecular mechanisms of lung cancer. Chest 109:145-195, 1996
21. Harley C, Kim N: Telomerase and cancer, in DeVita VJ, Hellman S, Rosenberg S (eds): Important Advances in Oncology. Philadelphia, PA, Lippincott-Raven, 1997, pp 1-11
22. Carbone D: The biology of lung cancer. Semin Oncol 24:388-401, 1997
23. Hiyama K, Ishioka S, Shirotani Y, et al: Alterations in telomeric repeat length in lung cancer are associated with loss of heterozygosity in P53 and rb. Oncogene 10:937-944, 1995
24. Downward J: The Ras superfamily of small GTP-binding proteins. Trends Biol Sci 15:469-472, 1990
25. de Vries J, ten Kate J, Bosnian F: p21ras in carcinogenesis. Pathol Res Pract 192:658-668, 1996
26. Fayad L, O'Brien S: Chronic lymphocytic leukemia and associated disorders, in Pazdur R (ed): Medical Oncology: A Comprehensive Review (ed 2). New York, NY, PRR, Inc, 1995, pp 37-56
27. Slebos R, Rodenhuis S: The ras gene family in human non-small cell lung cancer. JNCI Monogr 13:23-29, 1992
28. Mitsudomi T, Steinberg S, Oie H, et al: Ras gene mutations in non-small cell lung cancers are associated with shortened survival irrespective of treatment. Cancer Res 51:4999-5002, 1991
29. Slebos R, Kibbelaar R, Dalesio O, et al: K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. N Engl J Med 323:561-565, 1990
30. Harada M, Dosaka-Akita H, Miyamoto H, et al: Prognostic significance of the expression of ras oncogene product in non-small cell lung cancer. Cancer 69:72-77, 1992
31. Sugio K, Ishida T, Yokoyama T, et al: Ras gene mutations as a prognostic marker in adenocarcinoma of the human lung without lymph node metastasis. Cancer Res 52:2903-2906, 1992
32. Rosell R, Li S, Skacel Z: Prognostic impact of mutated K-ras gene in surgically resected non-small cell lung cancer patients. Oncogene 8:2407-2412, 1993
33. Sklar MD: The ras oncogenes increase the intrinsic resistance of NIH 3T3 cells to ionizing radiation. Science 239:645-647, 1988
34. Sklar MD: Increased resistance to cis-diamminedichloroplatinum(II) in NIH 3T3 cells transformed by ras oncogenes. Cancer Res 48:793-797, 1988
35. Rodenhuis S, Boerrigter L, Top B, et al: Mutational activation of the K-ras oncogene and the effect of chemotherapy in advanced adenocarcinoma of the lung: A prospective study. J Clin Oncol 15:285-291, 1997
36. Battey J, Moulding C, Taub R, et al: The human c-myc oncogene: Structural consequences of translocation into the IgH locus in Burkitt lymphoma. Cell 34:779-787, 1983
37. Taub R, Kirsch I, Morton C, et al: Translocations of the c-myc gene into the immunoglobulin heavy chain locus in human Burkitt lymphoma and murine plasmacytoma cells. Proc Natl Acad Sci USA 79:7837-7841, 1982
38. Dalla-Favera R, Bregni M, Erikson J, et al: Human c-myc oncogene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma. Proc Natl Acad Sci USA 79:7824-7827, 1982
39. Watson D, Reddy E, Duesberg P, et al: Nucleotide sequence analysis of chicken c-myc gene reveals homologous and unique coding regions by comparison with the transforming gene of avian myelocytomatosis virus MC29, delta gag-myc. Proc Natl Acad Sci USA 80:2146-2150, 1983
40. Blackwood E, Eisenman R: Max: A helix-loop-helix zipper protein that forms a sequence-specific DNA-binding complex with myc. Science 251:1211-1217, 1991
41. Lemaitre J-M, Buckle R, Mechali M: c-myc in the control of cell proliferation and embryonic development. Adv Cancer Res 70:95-144, 1996
42. Land H, Chen A, Morgenstern J, et al: Behavior of myc and ras oncogenes in transformation of rat embryo fibroblasts. Mol Cell Biol 6:1917-1925, 1986
43. Paget S: The distribution of secondary growths in cancer of the breast. Lancet 1:571-573, 1989
44. Prins J, De Vries E, Mulder N: The myc family of oncogenes and their presence and importance in small-cell lung carcinoma and other tumour types. Anticancer Res 13:1373-1385, 1993
45. Brennan J, O'Connor T, Makuch R, et al: myc family DNA amplification in 107 tumors and tumor cell lines from patients with small cell lung cancer treated with different combination chemotherapy regimens. Cancer Res 51:1708-1712, 1991
46. Noguchi M, Hirohasi S, Hara F: Heterogeneous amplification of myc family oncogenes in small cell lung carcinoma. Cancer 66:2053-2058, 1990
47. Funa K, Steinholtz L, Nou E, et al: Increased expression of N-myc in human small cell lung cancer biopsies predict lack of response to chemotherapy and poor prognosis. J Clin Pathol 88:216-220, 1986
48. Johnson B, Ihde D, Makuch R, et al: myc family oncogene amplification in tumor cell lines established from small cell lung cancer patients and its relationship to clinical status and course. J Clin Invest 79:1629-1634, 1987
49. Takahashi T, Obata Y, Sekido Y, et al: Expression and amplification of myc gene family in small cell lung cancer and its relation to biological characteristics. Cancer Res 49:2683-2688, 1989
50. Slebos R, Evers S, Wagenaar S, et al: Cellular protooncogenes are infrequently amplified in untreated non-small lung cancer. Br J Cancer 59:76-80, 1989
51. Kawashima K, Nomura S, Hirai H, et al: Correlation of the L-myc RFLP with metastasis, prognosis and multiple cancer in the lung cancer patients. Int J Cancer 50:557-561, 1992
52. Mountain CF: New prognostic factors in lung cancer - Biologic prophets of cancer cell aggression. Chest 108:246-254, 1995
53. Hung M-C, Schechter A, Chevray P-YM, et al: Molecular cloning of the neu gene: Absence of gross structural alteration in oncogenic alleles. Proc Natl Acad Sci USA 83:261-264, 1986
54. Coussens L, Yang-Feng T-L, Liao Y-C, et al: Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 230:1132-1139, 1985
55. Schecter A, Stern D, Vaidyanathan L, et al: The neu oncogene: An erb-B-related gene encoding a 185,000-Mr tumour antigen. Nature 312:513-516, 1984
56. Semba K, Kamata N, Toyoshima K, et al: A v-erbB-related protooncogene, c-erbB-2, is distinct from the c-erB-1/epidermal growth factor-receptor gene and is amplified in a human salivary gland adenocarcinoma. Proc Natl Acad Sci USA 82:6497-6501, 1985
57. Yamamoto T, Ikawa S, Akiyama T, et al: Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor. Nature 319:230-234, 1986
58. Hung M-C, Matin A, Zhang Y, et al: HER-2/neu-targeting gene therapy - A review. Gene 159:65-71, 1995
59. Ullrich A, Schlessinger J: Signal transduction by receptors with tyrosine kinase activity. Cell 61:203-212, 1990
60. Aaronson S: Growth factors and cancer. Science 254:1146-1153, 1991
61. Carpenter G, Soler C, Baulida J, et al: Interaction of signaling and trafficking proteins with the carboxyterminus of the epidermal growth factor receptor. Ann NY Acad Sci 766:44-51, 1995
62. Noguchi M, Murakami M, Bennett W, et al: Biological consequences of overexpression of a transfected c-erbB-2 gene in immortalized human bronchial epithelial cells. Cancer Res 53:2035-2043, 1993
63. Stocklin E, Botteri F, Groner B: An activated allele of the c-erbB-2 oncogene impairs kidney and lung function and causes early death of transgenic mice, J Cell Biol 122:199-208, 1993
64. neu expression in human lung adenocarcinomas predicts shortened survival. Cancer Res 50:5184-5191, 1990
65. Kern J, Filderman A: Oncogenes and growth factors in human lung cancer. Clin Chest Med 14:31-41, 1993
66. Tsujimoto Y, Finger L, Yunis J, et al: Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation. Science 226:1097-1099, 1984
67. Cleary M, Smith S, Sklar J: Cloning and structural analysis of cDNAs for bcl-2 and a hybrid bcl-2/immunoglobulin transcript resulting from the t(14;18) translocation. Cell 47:19-28, 1986
68. Hale AJ, Smith CA, Sutherland LC, et al: Apoptosis: Molecular regulation of cell death. Eur J Biochem 236:1-26, 1996
69. Novack DV, Korsmeyer SJ: Bcl-2 protein expression during murine development. Am J Pathol 145:61-73, 1994
70. Krajewski S, Krajewska M, Shabaik A, et al: Immunohistochemical determination of in vivo distribution of Bax, a dominant inhibitor of Bcl-2. Am J Pathol 145:1323-1336, 1994
71. Krajewski S, Bodrug S, Gascoyne R, et al: Immunohistochemical analysis of Mcl-1 and Bcl-2 proteins in normal and neoplastic lymph nodes. Am J Pathol 145:515-525, 1994
72. Korsmeyer S: Regulators of cell death. Trends Genet 11:101-105, 1995
73. Nakayama K, Nakayama K, Negishi I, et al: Targeted disruption of Bcl-2 alpha beta in mice: Occurrence of gray hair, polycystic kidney disease, and lymphocytopenia. Proc Natl Acad Sci USA 91:3700-3704, 1994
74. Kamada S, Shimono A, Shinto Y, et al: bcl-2 deficiency in mice leads to pleiotropic abnormalities: Accelerated lymphoid cell death in thymus and spleen, polycystic kidney, hair hypopigmentation, and distorted small intestine. Cancer Res 55:354-359, 1995
75. Sorenson CM, Rogers SA, Korsmeyer SJ, et al: Fulminant metanephric apoptosis and abnormal kidney development in bcl-2-deficient mice. Am J Physiol 268:73-81, 1995
76. Miyashita T, Krajewski S, Krajewska M, et al: Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene 9:1799-1805, 1994
77. Farrow S, Brown R: New members of the bcl-2 family and their protein partners. Curr Opin Genet Dev 6:45-49, 1996
78. Sedlak T, Oltvai Z, Yang E, et al: Multiple bcl-2 family members demonstrate selective dimerisations with bax. Proc Natl Acad Sci USA 92:7834-7838, 1995
79. Oltvai Z, Milliman C, Korsmeyer S: Bcl-2 heterodimerises in vivo with a conserved homolog, BAX, that accelerates programmed cell death. Cell 74:609-619, 1993
80. Pezzella F, Turley H, Kuzu I, et al: bcl-2 protein in non-small-cell lung carcinoma. N Engl J Med 329:690-694, 1993
81. Uren A, Vaux D: Molecular and clinical aspects of apoptosis. Pharmacol Ther 72:37-50, 1996
82. Yunis J, Ramsay N: Retinoblastoma and subband deletion of chromosome 13. Am J Dis Child 132:161-163, 1978
83. Knudson A: Hereditary cancer: Clues to mechanisms of carcinogenesis. Br J Cancer 59:661-666, 1989
84. Ewen ME: The cell cycle and the retinoblastoma protein family. Cancer Metast Rev 13:45-66, 1994 (review)
85. Sherr C: Cancer cell cycles. Science 274:1672-1677, 1996
86. Sherr C: Mammalian G1 cyclins. Cell 73:1059-1065, 1993
87. Elledge S: Cell cycle checkpoints: Preventing an identity crisis. Science 274:1664-1672, 1996
88. Ewen M, Sluss H, Whitehouse L, et al: TGF beta inhibition of Cdk 4 synthesis is linked to cell cycle arrest. Cell 74:1009-1020, 1993
89. Dowdy S, Hinds P, Louie K, et al: Physical interaction of the retinoblastoma protein with human D cyclins. Cell 73:499-511, 1993
90. Hinds P, Mittnacht S, Dulic V, et al: Regulation of retinoblastoma protein functions by ectopic expression of human cyclins. Cell 70:993-1006, 1992
91. Hinds P, Dowdy S, Eaton E, et al: Function of a human cyclin gene as an oncogene. Proc Natl Acad Sci USA 91:709-713, 1994
92. Kamb A, Shattuck-Eidens D, Liu Q, et al: Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus. Nat Genet 8:23-26, 1994
93. el-Deiry W, Tokino T, Velculescu V, et al: WAF1, a potential mediator of p53 tumor suppression. Cell 75:817-825, 1993
94. Toyoshima H, Hunter T: P27, a novel inhibitor of G1 cyclin-cdk protein kinase activity, is related to p21. Cell 78:67-74, 1994
95. Xiong Y, Hannon G, Zhang H, et al: P21 is a universal inhibitor of cyclin kinases. Nature 366:701-707, 1993
96. Shirodkar S, Ewen M, DeCaprio J, et al: The transcription factor E2F interacts with the retinoblastoma product and a p107-cyclin A complex in a cell cycle-regulated manner. Cell 68:157-166, 1992
97. Nevins J: E2F: A link between the Rb tumor suppressor protein and viral oncoproteins. Science 258:424-429, 1992
98. Weintraub S: Inactivation of tumor suppressor proteins in lung cancer. Am J Respir Cell Mol Biol 15:150-155, 1996
99. Harbour J, Lai S, Whang-Peng J, et al: Abnormalities in structure and expression of the retinoblastoma gene in SCLC. Science 241:353-357, 1988
100. Melnyk A, Rodriguez A: Intermediate- and high-grade non-Hodgkin's lymphomas, in Pazdur R (eds): Medical Oncology. A Comprehensive Review (ed 2). New York, NY, PRR, Inc, 1995, pp 99-110
101. Kaelin W, Ewen M, Livingston D: Definition of the minimal simian virus 40 large t antigen- and adenovirus E1A-binding domain in the retinoblastoma gene product. Mol Cell Biol 10:3761-3769, 1990
102. Hu Q, Dyson N, Harlow E: The regions of the retinoblastoma protein needed for binding to adenovirus or SV40 large T antigen are common sites for mutations. EMBO J 9:1147-11551, 1990
103. Huang S, Wang N, Tseng B, et al: Two distinct and frequently mutated regions of retinoblastoma protein are required for binding to SV40 T antigen. EMBO J 9:1815-1822, 1990
104. Shimizu E, Coxon A, Otterson G, et al: RB protein status and clinical cprrelation from 171 cell lines representing lung cancer, extrapulmonary small cell carcinoma, and mesothelioma. Oncogene 9:2441-2448, 1994
105. Xu H, Hu S, Cagle P, et al: Absence of retinoblastoma protein exopression in primary non-small cell lung carcinomas. Cancer Res 51:2735-2739, 1991
106. Carbone D, Kratzke R: RB1 and p53 genes, in Mitchell J, Johnson D, Turrisi A (eds): Lung Cancer: Principles and Practice. Philadelphia, PA. Lippincott-Raven, 1996, pp 107-121
107. Sidransky D, Hollstein M: Clinical implications of the p53 gene. Annu Rev Med 47:285-301, 1996
108. Cho Y, Gorina S, Jeffrey PD, et al: Crystal structure of a p53 tumor suppressor-DNA complex: Understanding tumorigenic mutations [see comments]. Science 265:346-355, 1994
109. Donehower LA, Harvey M, Slagle BL, et al: Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 356:215-221, 1992
110. Harper J, Adami G, Wei N, et al: The p21 Cdk-interacting protein CIP1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75:805-816, 1993
111. Flores-Rozas H, Kelman Z, Dean F, et al: Cdk-interacting protein 1 directly binds with prroliferating cellnuclear antigen and inhibits DNA polymerase (holoenzyme). Proc Natl Acad Sci USA 91:8655-8659, 1994
112. Chen J, Jackson M, Kirschner M, et al: Separate domains of p21 involved in the inhibition of CDK kinase and PCNA. Nature 374:386-388, 1995
113. Parker S, Eichele G, Zhang P, et al: p53-independent expression of p21CIP1 in muscle and other terminally differentiating cells. Science 267:1024-1026, 1995
114. Waga S, Hannon G, Beach D, et al: The p21 inhibitor of cyclin-dependent kinase controls DNA replication by interaction with PCNA. Nature 369:574-578, 1994
115. Smith M, Chen I-T, Zhan Q, et al: Interaction of the p53-regulated protein Gadd45 with proliferating cell nuclear antigen. Science 266:1376-1380, 1994
116. Steller H: Mechanisms and genes of cellular suicide. Science 267:1445-1449, 1995
117. Miyashita T, Reed J: Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 80:293-299, 1995
118. Lowe S, Bodis S, McClatchey A, et al: p53 status and the efficacy of cancer therapy in vivo. Science 266:807-810, 1994
119. Greenblatt M, Bennett W, Hollstein M, et al: Mutations in the p53 tumor suppressor gene: Clues to cancer etiology and molecular pathogenesis. Cancer Res 54:4855-4878, 1994
120. Malkin D: Germline p53 mutations and heritable cancer. Annu Rev Genet 28:443-465, 1994
121. Mitsudomi T, Lam S, Shirakusa T, et al: Detection and sequencing of p53 gene mutations in bronchial biopsy samples in patients with lung cancer. Chest 104:362-365, 1993
122. Lee J, Yoon A, Kalapurakal S, et al: Expression of p53 oncoprotein in non-small-cell lung cancer: A favorable prognostic factor. J Clin Oncol 13:1893-1903, 1995
123. Serrano M, Hannon GJ, Beach D: A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 366:704-707, 1993
124. Serrano M, Lee H, Chin L, et al: Role of the INK4A locus in tumor suppression and cell mortality. Cell 85:27-37, 1996
125. Shapiro GI, Edwards CD, Kobzik L, et al: Reciprocal Rb inactivation and p16INK4 expression in primary lung cancers and cell lines. Cancer Res 55:505-509, 1995
126. Okamoto A, Hussain SP, Hagiwara K, et al: Mutations in the p16INK4/MTS1/CDKN2, p15INK4B/MTS2, and p18 genes in primary and metastatic lung cancer. Cancer Res 55:1448-1451, 1995
127. Mulshine J, Tockman M, Smart C: Considerations in the development of lung cancer screening tools. J Natl Cancer Inst 81:900-905, 1989
128. Mao L, Hruban R, Boyle R, et al: Detection of oncogene mutations in sputum precedes diagnosis of lung cancer. Cancer Res 54:1634-1637, 1994
129. Birrer M, Brown P: Application of molecular genetics to the early diagnosis and screening of lung cancer. Cancer Res 52:2658s-2664s, 1992
130. Strauss GM, Kwiatkowski DJ, Harpole DH, et al: Molecular and pathologic markers in stage I non-small-cell carcinoma of the lung. J Clin Oncol 13:1265-1279, 1995
131. Tockman M, Erozan Y, Gupta P, et al: The early detection of second primary lung cancers by sputum immunostaining. Chest 106: 385S-390S, 1994
132. Scott F, Cuttitta F, Treston A, et al: Prospective trial evaluating immunocytochemical-based sputum techniques tor early lung cancer detection: Assays for promotion factors in the bronchial lavage. J Cell Biochem 17F:175-183, 1993
133. Nuorva K, Soini Y, Kamel D, et al: Concurrent p53 expression in bronchial dysplasias and squamous cell lung carcinomas. Am J Pathol 142:725-732, 1993
134. Zalcman G, Tredaniel J, Hirsh A, et al: Detection and sequencing of p53 gene mutations in bronchial biopsy samples in patients with lung cancer. Chest 106:1309-1310, 1994
135. Winter S, Minna J, Johnson B, et al: Development of antibodies against p53 in lung cancer patients appears to be dependent on the type of p53 mutation. Cancer Res 52:4168-4174, 1992
136. Hussein A: The potential applications of gene transfer in the treatment of patients with cancer: A concise review. Cancer Invest 14:343-352, 1996
137. Lee C-T, Chen HL, Carbone DP: Gene therapy for lung cancer. Ann Oncol 6:61-63, 1995
138. Guild B, Finer M, Housman D: Development of retrovirus vectors useful for expressing genes in cultured murine embryonal cells and hematopoietic cells in vivo. J Virol 62:3795-3801, 1988
139. Curiel DT, Pilewski JM, Albelda SM: Gene therapy approaches for inherited and acquired lung diseases. Am J Respir Cell Mol Biol 14:1-18, 1996
140. Sambrook J, Fritsch E, Maniatis T: Molecular Cloning: a Laboratory Manual. Cold Spring Harbor, NY, Cold Spring Harbor Laboratory, 1989
141. Cai D, Mukhopadhyay T, Liu Y, et al: Stable expression of the wild-type p53 gene in human lung cancer cells after retrovirus-mediated gene transfer. Hum Gene Ther 4:617-624, 1993
142. Harris C: p53 tumor suppressor gene: From the basic research laboratory to the clinic - An abridged historical perspective. Carcinogenesis 17:1187-1198, 1996
143. Minna J, Gazdar A: Translational research comes of age. Nat Med 2:974-975, 1996
144. Zhang W-W: Antisense oncogene and tumor suppressor gene therapy of cancer. J Mol Med 74:191-204, 1996
145. Roth JA, Nguyen D, Lawrence DD, et al: Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer. Nat Med 2:985-991, 1996
146. Nguyen D, Spitz F, Yen N, et al: Gene therapy for lung cancer: Enhancement of tumor suppression by a combination of sequential systemic cisplatin and adenovirus-mediated p53 gene transfer. J Thorac Cardiovasc Surg 112:1372-1377, 1996
147. Zhang Y, Mukhopadhyay T, Donehower L, et al: Retroviral vector-mediated transduction of K-ras antisense RNA into human lung cancer cells inhibits expression of the malignant phenotype. Hum Gene Ther 4:451-460, 1993
148. Robinson LA, Smith LJ, Fontaine MP, et al: c-myc antisense oligodeoxyribonucleotides inhibit proliferation of non-small cell lung cancer. Ann Thorac Surg 60:1583-1591, 1995